These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

668 related articles for article (PubMed ID: 30617136)

  • 1. Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15.
    Chen Y; Sun C; Landoni E; Metelitsa L; Dotti G; Savoldo B
    Clin Cancer Res; 2019 May; 25(9):2915-2924. PubMed ID: 30617136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced
    Xu X; Huang W; Heczey A; Liu D; Guo L; Wood M; Jin J; Courtney AN; Liu B; Di Pierro EJ; Hicks J; Barragan GA; Ngai H; Chen Y; Savoldo B; Dotti G; Metelitsa LS
    Clin Cancer Res; 2019 Dec; 25(23):7126-7138. PubMed ID: 31484667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma.
    Singh N; Liu X; Hulitt J; Jiang S; June CH; Grupp SA; Barrett DM; Zhao Y
    Cancer Immunol Res; 2014 Nov; 2(11):1059-70. PubMed ID: 25104548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model.
    Richman SA; Nunez-Cruz S; Moghimi B; Li LZ; Gershenson ZT; Mourelatos Z; Barrett DM; Grupp SA; Milone MC
    Cancer Immunol Res; 2018 Jan; 6(1):36-46. PubMed ID: 29180536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.
    Prapa M; Caldrer S; Spano C; Bestagno M; Golinelli G; Grisendi G; Petrachi T; Conte P; Horwitz EM; Campana D; Paolucci P; Dominici M
    Oncotarget; 2015 Sep; 6(28):24884-94. PubMed ID: 26298772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced anti-tumor activity mediated by combination chimeric antigen receptor T cells targeting GD2 and GPC2 in high-risk neuroblastoma.
    Wu H; Zhang G; Liu Z; Liu W; Wang X; Zhao Y
    Cytotherapy; 2024 Nov; 26(11):1308-1319. PubMed ID: 38904586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.
    Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers.
    Fischer-Riepe L; Kailayangiri S; Zimmermann K; Pfeifer R; Aigner M; Altvater B; Kretschmann S; Völkl S; Hartley J; Dreger C; Petry K; Bosio A; von Döllen A; Hartmann W; Lode H; Görlich D; Mackensen A; Jungblut M; Schambach A; Abken H; Rossig C
    Clin Cancer Res; 2024 Aug; 30(16):3564-3577. PubMed ID: 38593230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer.
    Reppel L; Tsahouridis O; Akulian J; Davis IJ; Lee H; Fucà G; Weiss J; Dotti G; Pecot CV; Savoldo B
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35022195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy.
    Heczey A; Liu D; Tian G; Courtney AN; Wei J; Marinova E; Gao X; Guo L; Yvon E; Hicks J; Liu H; Dotti G; Metelitsa LS
    Blood; 2014 Oct; 124(18):2824-33. PubMed ID: 25049283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma.
    Moghimi B; Muthugounder S; Jambon S; Tibbetts R; Hung L; Bassiri H; Hogarty MD; Barrett DM; Shimada H; Asgharzadeh S
    Nat Commun; 2021 Jan; 12(1):511. PubMed ID: 33479234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
    Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of MEK pathway enhances the antitumor efficacy of chimeric antigen receptor T cells against neuroblastoma.
    Tomida A; Yagyu S; Nakamura K; Kubo H; Yamashima K; Nakazawa Y; Hosoi H; Iehara T
    Cancer Sci; 2021 Oct; 112(10):4026-4036. PubMed ID: 34382720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas.
    Long AH; Highfill SL; Cui Y; Smith JP; Walker AJ; Ramakrishna S; El-Etriby R; Galli S; Tsokos MG; Orentas RJ; Mackall CL
    Cancer Immunol Res; 2016 Oct; 4(10):869-880. PubMed ID: 27549124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAR T-cell-mediated delivery of bispecific innate immune cell engagers for neuroblastoma.
    Pascual-Pasto G; McIntyre B; Hines MG; Giudice AM; Garcia-Gerique L; Hoffmann J; Mishra P; Matlaga S; Lombardi S; Shraim R; Schürch PM; Yarmarkovich M; Hofmann TJ; Alikarami F; Martinez D; Tsang M; Gil-de-Gómez L; Spear TT; Bernt KM; Wolpaw AJ; Dimitrov DS; Li W; Bosse KR
    Nat Commun; 2024 Aug; 15(1):7141. PubMed ID: 39164224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma.
    Batra SA; Rathi P; Guo L; Courtney AN; Fleurence J; Balzeau J; Shaik RS; Nguyen TP; Wu MF; Bulsara S; Mamonkin M; Metelitsa LS; Heczey A
    Cancer Immunol Res; 2020 Mar; 8(3):309-320. PubMed ID: 31953246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2.
    Gargett T; Brown MP
    Cytotherapy; 2015 Apr; 17(4):487-95. PubMed ID: 25573334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells.
    Tanaka M; Tashiro H; Omer B; Lapteva N; Ando J; Ngo M; Mehta B; Dotti G; Kinchington PR; Leen AM; Rossig C; Rooney CM
    Clin Cancer Res; 2017 Jul; 23(14):3499-3509. PubMed ID: 28183713
    [No Abstract]   [Full Text] [Related]  

  • 19. Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition.
    Perna SK; Pagliara D; Mahendravada A; Liu H; Brenner MK; Savoldo B; Dotti G
    Clin Cancer Res; 2014 Jan; 20(1):131-9. PubMed ID: 24097874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells.
    Du H; Hirabayashi K; Ahn S; Kren NP; Montgomery SA; Wang X; Tiruthani K; Mirlekar B; Michaud D; Greene K; Herrera SG; Xu Y; Sun C; Chen Y; Ma X; Ferrone CR; Pylayeva-Gupta Y; Yeh JJ; Liu R; Savoldo B; Ferrone S; Dotti G
    Cancer Cell; 2019 Feb; 35(2):221-237.e8. PubMed ID: 30753824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.